Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2020

01-09-2020 | Endocrine Methods and Techniques

Treating thyroid nodules by radiofrequency: is the delivered energy correlated with the volume reduction rate? A pilot study

Authors: Pierpaolo Trimboli, Maurilio Deandrea

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Objective

Radiofrequency ablation (RFA) was proven as effective in reducing thyroid nodules’ volume. However, whether technical procedure aspects could influence the volume reduction rate (VRR) has not been clarified. This retrospective pilot study aimed to analyze the correlation of RFA power, duration, and energy with VRR.

Methods

During the period from June to December 2018 two primary-care centers treated benign thyroid nodules of adult outpatients according to the same RFA procedure. Technical parameters to be investigated were the following: median power (Pmedian), effective time of treatment (Teff), energy calculated as Pmedian × Teff (Ecalc), and energy delivered per mL as Kcal × 4184 × nodule’s volume (Edel). Continuous variables were analyzed by the Mann–Whitney test. Data of 1-year posttreatment follow-up were collected on December 2019 and the correlation of the above parameters with VRR was analyzed by linear regression.

Results

Forty-one nodules were included and their 1-year VRR was 66.6%. RFA was performed with a Pmedian of 55 W, Teff 10.24 min, Ecalc 31,380 J, and Edel 1473 J/mL. Edel was significantly correlated with VRR (p = 0.014) while Pmedian, Teff, and Ecalc not. A strong correlation of Edel with VRR was found in nodules <10 mL (p = 0.001) while no significant correlation was observed in nodules >10 mL.

Conclusions

This study showed that the energy delivered with RFA is the only technical parameter significantly correlated with the VRR of thyroid nodules.
Literature
1.
J.B. Vander, E.A. Gaston, T.R. Dawber, The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann. Intern. Med. 69(3), 537–540 (1968)CrossRef
2.
W.M. Tunbridge, D.C. Evered, R. Hall et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin. Endocrinol. 7(6), 481–493 (1977)CrossRef
3.
S. Guth, U. Theune, J. Aberle, A. Galach, C.M. Bamberger, Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur. J. Clin. Investig. 39(8), 699–706 (2009)CrossRef
4.
L. Hegedüs, S.J. Bonnema, F.N. Bennedbaek, Management of simple nodular goiter: current status and future perspectives. Endocr. Rev. 24(1), 102–132 (2003)CrossRef
5.
S. Filetti, C. Durante, M. Torlontano, Nonsurgical approaches to the management of thyroid nodules. Nat. Clin. Pract. Endocrinol. Metab. 2(7), 384–394 (2006)CrossRef
6.
E. Papini, C.M. Pacella, L.A. Solbiati, G. Achille, D. Barbaro, S. Bernardi, V. Cantisani, R. Cesareo, A. Chiti, L. Cozzaglio, A. Crescenzi, F. De Cobelli, M. Deandrea, L. Fugazzola, G. Gambelunghe, R. Garberoglio, G. Giugliano, L. Luzi, R. Negro, L. Persani, B. Raggiunti, F. Sardanelli, E. Seregni, M. Sollini, S. Spiezia, F. Stacul, D. Van Doorne, L.M. Sconfienza, G. Mauri, Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group. Int. J. Hyperth. 36, 376–382 (2019). https://​doi.​org/​10.​1080/​02656736.​2019.​1575482CrossRef
7.
8.
J.H. Kim, J.H. Baek, H.K. Lim, H.S. Ahn, S.M. Baek, Y.J. Choi, Y.J. Choi, S.R. Chung, E.J. Ha, S.Y. Hahn, S.L. Jung, D.S. Kim, S.J. Kim, Y.K. Kim, C.Y. Lee, J.H. Lee, K.H. Lee, Y.H. Lee, J.S. Park, H. Park, J.H. Shin, C.H. Suh, J.Y. Sung, J.S. Sim, I. Youn, M. Choi, D.G. Na; Guideline Committee for the Korean Society of Thyroid Radiology (KSThR) and Korean Society of Radiology, 2017 Thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J. Radiol. 19, 632–655 (2018). https://​doi.​org/​10.​3348/​kjr.​2018.​19.​4.​632CrossRefPubMedPubMedCentral
9.
P. Trimboli, M. Castellana, L. M. Sconfienza, C. Virili, L. C. Pescatori, R. Cesareo, F. Giorgino, R. Negro, L. Giovanella, G. Mauri, Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: a systematic review and meta-analysis. Endocrine. (2019). https://​doi.​org/​10.​1007/​s12020-019-02019-3
10.
M. Deandrea, P. Trimboli, F. Garino et al. Long term efficacy of a single session RFA of benign thyroid nodules: a longitudinal 5-year observational study. J. Clin. Endocrinol. Metab. 104(9), 3751–3756 (2019)CrossRef
11.
R. Negro, M. Rucco, A. Creanza, A. Mormile, P. P. Limone, R. Garberoglio, S. Spiezia, S. Monti, C. Cugini, G. El Dalati, M. Deandrea, Machine learning prediction of radiofrequency thermal ablation efficacy: a new option to optimize thyroid nodule selection. Eur. Thyroid J. (2019). https://​doi.​org/​10.​1159/​000504882
12.
G. Gambelunghe, R. Fede, V. Bini, M. Monacelli, N. Avenia, M. D’Ajello, R. Colella, G. Nasini, P. De Feo, Ultrasound-guided interstitial laser ablation for thyroid nodules is effective only at high total amounts of energy: results from a three-year pilot study. Surg. Innov. 20, 345–350 (2013). https://​doi.​org/​10.​1177/​1553350612459276​CrossRefPubMed
13.
J.H. Baek, Y.S. Kim, D. Lee, J.Y. Huh, J.H. Lee, Benign predominantly solid thyroid nodules: prospective study of efficacy of sonographically guided radiofrequency ablation versus control condition. AJR Am. J. Roentgenol. 194, 1137–1142 (2010)CrossRef
14.
W.K. Jeong, J.H. Baek, H. Rhim, J.S. Kim, M.S. Kwak, H.J. Jeong, D. Lee, Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur. Radiol. 18, 1244–1250 (2008)CrossRef
15.
W.J. Moon, J.H. Baek, S.L. Jung, D.W. Kim, E.K. Kim, J.Y. Kim, J.Y. Kwak, J.H. Lee, J.H. Lee, Y.H. Lee, D.G. Na, J.S. Park, S.W. Park, Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J. Radiol. 12, 1–14 (2011)CrossRef
16.
S.N. Goldberg, J.W. Charboneau, G.D. Dodd 3rd, D.E. Dupuy, D.A. Gervais, A.R. Gillams, R.A. Kane, F.T. Lee Jr, T. Livraghi, J.P. McGahan, H. Rhim, S.G. Silverman, L. Solbiati, T.J. Vogl, B.J. Wood, Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 228, 335–345 (2003)CrossRef
17.
D. Sacks, T.E. McClenny, J.F. Cardella, C.A. Lewis, Society of interventional radiology clinical practice guidelines. J. Vasc. Interv. Radiol. 14, S199–S202 (2003)CrossRef
18.
19.
20.
M. Deandrea, F. Garino, M. Alberto, R. Garberoglio, R. Rossetto, N. Bonelli, S. Spiezia, M. De Santis, S. Monti, M.G. Deiana, T. Vincenzo, C. Cugini, G. El Dalati, P.P. Limone, Radiofrequency ablation for benign thyroid nodules according to different ultrasound features: an Italian multicentre prospective study. Eur. J. Endocrinol. 180, 79–87 (2019). https://​doi.​org/​10.​1530/​EJE-18-0685CrossRefPubMed
21.
Metadata
Title
Treating thyroid nodules by radiofrequency: is the delivered energy correlated with the volume reduction rate? A pilot study
Authors
Pierpaolo Trimboli
Maurilio Deandrea
Publication date
01-09-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02275-8

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue

Endocrine Imaging

Large intrathyroidal lipoma with radioiodine uptake

Correction

Correction to: MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives

Original Article

Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism

Viewpoint

Mechanism of higher risk for COVID-19 in diabetes: a mask to lift

Viewpoint

Should everolimus be stopped after radiological progression in metastatic insulinoma? A “cons” point of view

Original Article

Association between changes in bioactive osteocalcin and glucose homeostasis after biliopancreatic diversion
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits